| Chapter title |
Translational Pharmacology in Glaucoma Neuroprotection
|
|---|---|
| Chapter number | 20 |
| Book title |
Pharmacologic Therapy of Ocular Disease
|
| Published in |
Handbook of experimental pharmacology, January 2016
|
| DOI | 10.1007/164_2016_20 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-958288-7, 978-3-31-958290-0
|
| Authors |
Leonard A. Levin |
| Abstract |
Glaucoma is both the most common optic neuropathy worldwide and the most common cause of irreversible blindness in the world. The only proven treatment for glaucomatous optic neuropathy is lowering the intraocular pressure, achieved with a variety of pharmacological, laser, and surgical approaches. Over the past 2 decades there has been much basic and clinical research into achieving treatment of the underlying optic nerve damage with neuroprotective approaches. However, none has resulted in regulatory approval based on successful phase 3 studies. This chapter discusses the reasons for this "lost in translation" aspect of glaucoma neuroprotection, and outlines issues at the laboratory and clinical trial level that need to be addressed for successful development of neuroprotective therapies. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 8% |
| Unknown | 12 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 23% |
| Student > Master | 3 | 23% |
| Student > Bachelor | 1 | 8% |
| Other | 1 | 8% |
| Student > Postgraduate | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 54% |
| Computer Science | 1 | 8% |
| Design | 1 | 8% |
| Unknown | 4 | 31% |